BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//CTMSS - ECPv6.7.0//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:CTMSS
X-ORIGINAL-URL:https://clinicaltmssociety.org
X-WR-CALDESC:Events for CTMSS
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:UTC
BEGIN:STANDARD
TZOFFSETFROM:+0000
TZOFFSETTO:+0000
TZNAME:UTC
DTSTART:20190101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210113
DTEND;VALUE=DATE:20241108
DTSTAMP:20260423T090019
CREATED:20241107T195428Z
LAST-MODIFIED:20241108T134541Z
UID:1502-1610496000-1731023999@clinicaltmssociety.org
SUMMARY:January 13\, 2021 Town Hall Member Meeting
DESCRIPTION:January 13\, 2021 Annual Town Hall Member Meeting  \nYou’re invited to join the Clinical TMS Society for the January 13\, 2021 Annual Town Hall Member Meeting.  \nPresentation Overview:  \nJoin the Clinical TMS Society President\, Kimberly Cress\, MD\, President-Elect\, Randy Pardell\, MD\, and our current committee co-chairs for an update on all 2020-2021 committee projects. \nThis is your opportunity to learn more about the various goals and projects\, ask questions and provide feedback. \nDate: January 13\, 2021 \nFormat: ON-DEMAND \nThis meeting is for current members only.  \n\nSPEAKERS:  \nJohn O'Reardon\, MD\, CTMSS Annual Meeting Committee Co-chair\nDr. O’Reardon has been in practice as a psychiatrist for 30 years. He completed his residency training at Penn and Fellowships in Psychopharmacology & Cognitive Therapy (including training at the Beck Institute). In his clinical work as a faculty member at Penn he focused on treatment-resistant mood disorders and neuromodulation. This is the development of brain devices to stimulate the brain and treat mood disorders. These devices\, which are increasing all the time\, include transcranial magnetic stimulation (TMS)\, deep brain stimulation (DBS)\, vagus nerve stimulation (VNS)\, EEG-synchronized TMS (sTMS)\, deep TMS (dTMS) and transcranial direct current stimulation (tDCS). \nDr. O’Reardon was an active educator at Penn and over the years helped train more than a hundred psychiatry residents. He taught courses on neuromodulation\, mood disorders and the History of Psychiatry. He has been a recipient of numerous teaching awards including the Earl Bond Award for excellence in teaching. He has been a frequent presenter at the annual meeting of the American Psychiatric Association (APA). Most recently he has presented a symposium on historical figures and mood disorders called Art\, Politics and Creativity: Resilience in the Face of Great Odds – including Abraham Lincoln\, Vincent Van Gogh\, Winston Churchill and Sylvia Plath. \nDr. O’Reardon has been an active and productive researcher during his career. He has authored over a hundred publications in his career encompassing new brain devices (TMS\, sTMS\, VNS\, DBS and tDCS)\, major depression\, bipolar disorder\, ECT and the night eating syndrome. He has been a lead investigator in many cutting edge clinical trials of new treatments for patients. He is first author on the primary trial that led to FDA approval for TMS as new exciting treatment for major depression. His current research work is with another exciting emerging treatment modality for major depression\, namely tDCS. \nSuzanne Kerns\, MD\, CTMSS Education Committee Co-chair\nDr. Suzanne Kerns is an Assistant Professor of Psychiatry in the Brain Stimulation Service at the Medical University of South Carolina. She serves as the Co-Chair of the Education Committee\, alongside Dr. Michelle Cochran\, and sits on the Board of Directors of the Clinical TMS Society.  Dr. Kerns is experienced in the use of a variety of neuromodulation techniques including ECT\, TMS\, DBS\, and VNS. Her special interests include expanding the use of brain stimulation within Women's mental health\, neuromodulation education\, and holistic and integrative approaches to brain health. \nMartha Koo\, MD\, CTMSS Research Committee Co-chair\nMartha B Koo\, M.D\, has offered psychiatry and psychoanalysis in her private practice in Manhattan Beach\, CA\, since 1996. In 2009\, she certified in Transcranial Magnetic Stimulation. She is the Founder of Neuro Wellness Spa\, a mental health company with four locations that offers rTMS\, IV ketamine\, iV nutrition and photobiomodulation. Dr. Koo joined the CTMSS Board of Directors in 2020 and is co-chair of the Research Committee. \nMohamed Abdelghani\, MBBCh\, MSc\, MRCPsych\, CTMSS Outreach Committee Co-chair\nDr Mohamed Abdelghani is a consultant psychiatrist in London in the UK. He founded the first clinical TMS service in the NHS (public sector) in London and South England. He is actively involved in TMS clinical research and he is the London Principal Investigator for the BRIGhTMIND TMS Randomised Control Trial. In addition to the TMS service he runs in the NHS Dr Abdelghani also offers TMS through his private clinic. \nPaul Croarkin\, DO\, CTMSS Clinical Standards Committee Co-chair\nDr. Croarkin’s research program focuses on adapting and innovating brain stimulation interventions in children and adolescents.  This includes biomarker work to optimize diagnostic practices and the delivery of brain based interventions such as transcranial magnetic stimulation.  A central theme focuses on the role of gamma-aminobutyric acid (GABA) and glutamate neurotransmitter systems in early-onset mood disorders with the goal of informing safer and more effective biologic treatments. Dr. Croarkin is a professor of psychiatry in the Mayo Clinic College of Medicine. \nRebecca Allen\, MD\, CTMSS Insurance Committee Co-chair\nDr. Allen has authored several papers and participated in research on sleep and memory consolidation\, quality of life in multiple sclerosis\, comparing TMS protocols and other projects. She authored a chapter on Sleep and Sleep Disorders for the Harvard textbook Neuropsychiatry and Behavioral Neurology: Principles and Practice (2020).  Her main clinical interest is neuropsychiatry: she is trained in the neurobiological bases and treatment of cognitive and behavioral manifestations of neurodegenerative diseases (dementia)\, multiple sclerosis\, epilepsy\, stroke\, brain tumors\, developmental disorders\, traumatic brain injury and other disorders. Other clinical interests include electroconvulsive therapy\, transcranial magnetic stimulation\, and the interaction between sleep and psychiatric disorders. She has held local and national leadership positions\, including serving on the Board of the Clinical TMS Society and as the President of the Washington State Psychiatric Association for 2020-21. \nKen Goolsby\, MD\, CTMSS Membership Committee Co-chair\nKenneth E. Goolsby\, MD has been in private practice in Gainesville since 1987. As a child\, adolescent and adult psychiatrist\, he provides diagnostic evaluations\, individual and family psychotherapy\, medication evaluation and management\, crisis intervention\, and chemical dependency evaluations. Dr. Goolsby provides inpatient hospital care as well as outpatient care. \nDr. Goolsby earned his bachelor's degree at the University of Georgia and his medical degree at the Medical College of Georgia. He completed his psychiatric residency at the William S. Hall Psychiatric Institute Emory University. He then completed his child psychiatry fellowship at William S. Hall Psychiatric Institute. He is a diplomate of the American Board of Psychiatry and Neurology. \nIan Cook\, MD\, CTMSS Legal\, Business\, and Ethics Commitee Co-chair\nIan A. Cook\, M.D. holds the Joanne and George Miller and Family Endowed Chair in Depression Research. He is a Professor of Psychiatry and Biobehavioral Sciences in the David Geffen School of Medicine\, and a Research Scientist at the Semel Institute for Neuroscience and Human Behavior. Dr. Cook received his bachelors degree with high honors from Princeton University and his medical degree from the Yale University School of Medicine. He completed his psychiatry residency training at UCLA's Neuropsychiatric Institute\, where he also was an NIMH-funded research fellow. Dr. Cook served on the Executive Committee on Practice Guidelines of the American Psychiatric Association\, and guided the electronic dissemination of their evidence-based guidelines in psychiatry. A board-certified Psychiatrist\, he has also served as an examiner for the American Board of Psychiatry and Neurology. His biography is profiled in Who's Who in America\, Who's Who in the World\, and Best Doctors. He is the author of numerous publications on brain function in mental illness and in aging\, and holds several patents on biomedical devices and methods. \nMichelle Cochran\, MD\, CTMSS Education Committee Co-chair\, Practice Guidelines Committee Co-chair\, ACROSS Representative to APA\nDr. Cochran currently works as the medical director of the Nashville Center for Hope & Healing and the NeuroScience and TMS treatment centers; in addition she maintains a role as a private practice psychiatrist.  Dr Cochran has experience treating a variety of psychiatric conditions\, using a comprehensive approach with therapy\, counseling\, pharmacogenomic testing\, medication\, and neuromodulation. She received her undergraduate degree at Centre College\, her medical training at University of Louisville School of Medicine\, and she completed her postgraduate medical education at Vanderbilt University Medical Center in Nashville\, Tennessee. During her psychiatry residency she was Chief Resident.  Additionally\, she completed the Management Program for Physicians and Senior Healthcare Administrators at Vanderbilt University\, Owen School of Management.  A current diplomat of the American Board of Psychiatry and Neurology (with active maintenance of certification)\, Dr. Cochran is a member of the Tennessee Psychiatric Association\, Tennessee Medical Association\, Nashville Academy of Medicine\, Tennessee Women in Medicine\, and Southern Psychiatric Association. Since her residency years\, she has also been a member\, Fellow (2011)\, and now Distinguished Fellow (2018) of the American Psychiatric Association. Dr. Cochran has been on the Clinical Faculty in the Department of Psychiatry at Vanderbilt University Medical Center since 1996 and has lectured to undergraduate\, graduate\, and postgraduate students as well as private practitioners.  For over 15 years\, she has been active on numerous advisory boards professionally and personally.  Before retiring from inpatient psychiatric care and establishing her outpatient private practice\, she was the medical director for many psychiatric units and programs in the Middle Tennessee area. Since 2011\, Dr. Cochran has offered repetitive transcranial magnetic stimulation to her patients as an option for the treatment of Major Depressive Disorder.  Dr. Cochran and her staff have trained extensively in the use of repetitive transcranial Magnetic Stimulation (rTMS) including training at Berenson Allen’s Non-Invasive Brain Institute\, Duke University and other specific advanced device trainings.  She has been active in the Clinical TMS Society (CTMSS) on many levels including serving on the executive committee as the VP-Elect (2016-2017)\, President (2017-2018)\, and with the Education and Annual meeting committees.  Most recently she has been helping advance the PULSES introductory course with other active CTMSS board members. \nMODERATED BY:  \nRandy Pardell\, MD\, CTMSS President Elect\nDr. Pardell is currently the Vice President/President-elect of the Clinical TMS Society.  He has served on the Board of Directors of CTMSS for the past 4 years and has been elected to the Executive Committee as Member at Large for two terms and now as Vice President. He has been past Chairman of the Outreach Committee and has served on the Membership and Education Committees. He has been a returning lecturer for the CTMSS Pulses Course.   He has been practicing TMS therapy since 2009. He co-wrote the first lay book on TMS called 3000 Pulses. Dr. Pardell is an honors graduate of the University of Pennsylvania and New York University School of Medicine. He completed his residency and chief residency at the St. Luke’s Roosevelt Medical Center and Post-Doctoral Fellowship at Columbia University where he performed smoking cessation research with Alexander Glassman MD. After graduation from his psychiatric training\, Dr. Pardell moved up with his wife to the beautiful Hudson Valley\, New York to start a practice and raise a family. Dr. Pardell is a Distinguished Life Fellow of the American Psychiatric Association and has been a past President of the Mid-Hudson Psychiatric Society and had been its Program Director for over a decade. Dr. Pardell founded Riverview Psychiatric Medicine\, PC and TMS Center of the Hudson Valley and leads an active group psychiatric and TMS practice. 
URL:https://clinicaltmssociety.org/event/january-13-2021-town-hall-member-meeting/
CATEGORIES:On-Demand Webinars
ATTACH;FMTTYPE=image/jpeg:https://clinicaltmssociety.org/wp-content/uploads/2024/11/2021_Annual_Town_Hall_Member_Meeting_Thumbnail_V5.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20201118
DTEND;VALUE=DATE:20201119
DTSTAMP:20260423T090019
CREATED:20201107T195259Z
LAST-MODIFIED:20241118T202658Z
UID:1500-1605657600-1605743999@clinicaltmssociety.org
SUMMARY:CTMSS Product Theater Webinar with MAGVENTURE
DESCRIPTION:CTMSS Product Theater Webinar - ON-DEMAND\n \nDate: Wednesday\, November 18\, 2020\nFormat: On-Demand \nThe Advantages of Robotic TMS in The Context of The COVID-19 Pandemic \nThe TMS-Cobot is the only FDA cleared robotic TMS solution for MagVenture TMS Therapy. MagVenture is proud to be partners with Axilum Robotics in offering a solution to significantly eliminate patient operator contact during routine TMS procedures. \nWhat are the general advantages of The TMS-Cobot? \n\nThe TMS-Cobot\, with its optical Tracking System\, controls the real-time position\, orientation and tilt of the TMS coil during the session. There is no need for the operator to adjust coil position during the session.\nAutomatically compensates for potential head motion during the TMS session and reduces the movement constraint of the patient.\nMaintains contact between the coil and head with its integrated contact sensor.\n\nLearning objectives \n\nIntroduction to Robotic TMS;\nTMS-Cobot implementation and how it works to reduce patient and operator interaction;\nDemonstration of the FDA cleared TMS-Cobot.\n\nFormat: LIVE \nFREE TO REGISTER! \n**Webinar log-in information will be sent out via email. \nDisclaimer: The content does not necessarily reflect the views and opinions of the Clinical TMS Society or its members and is solely determined by the sponsor. \n\nPresenters: \n\nMichel Berg\, MD\, CEO of Axilum Robotics \nDr. Berg is a medical doctor and a business school graduate\, he built his experience within the pharmaceutical and medical device industry before co-founding Axilum Robotics in 2011 with a team of experts in medical robotics. \n\nRustin Berlow\, MD \nDr. Berlow is a psychiatrist in a California private practice with years of TMS experience. He graduated from Columbia University College of Physicians and Surgeons medical school in 1990. After 23 years of psychopharmacology Dr. Berlow added procedural diagnosis & brain stimulation. Initial visit includes HRV\, GSR and EEG. Magnetic stim: rTMS\, TBS\, accelerated\, deep TMS. Electric stim: tDCS\, tACS\, Trigeminal and tVNS (Transcutaneous Vagus Nerve Stimulation). EEG-TMS - how to predict and personalize treatment). \n\n\n\nWhen\nNovember 18th\, 2020 from  5:00 PM to  6:00 PM
URL:https://clinicaltmssociety.org/event/ctmss-product-theater-webinar-with-magventure/
CATEGORIES:On-Demand Webinars
ATTACH;FMTTYPE=image/jpeg:https://clinicaltmssociety.org/wp-content/uploads/2024/11/MagVenture_Product_Theater_Event_Thumbnail.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20200929
DTEND;VALUE=DATE:20241108
DTSTAMP:20260423T090019
CREATED:20241107T195053Z
LAST-MODIFIED:20241108T134600Z
UID:1498-1601337600-1731023999@clinicaltmssociety.org
SUMMARY:CTMSS Product Theater Webinar with NEUROSTAR
DESCRIPTION:CTMSS Product Theater Webinar\n \nDate: Tuesday\, September 29\, 2020\nTime: 5:00 pm PDT / 7:00 pm CDT / 8:00 pm EDT \nTreating Depression Episodes – New Research Data before Publication\nEfficacy of NeuroStar TMS in Bipolar and Unipolar Depression \nTreatment of Bipolar Depression: A Pilot Study presented by Scott Aaronson\, M.D. \nThe majority of time patients with bipolar disorder are ill\, they are depressed.  There are few FDA approved treatments for bipolar depression and all of them are second-generation antipsychotics which carry a high side effect burden.  Clinical experience has suggested that TMS might be effective for bipolar depression.  This presentation will review the existing literature on the efficacy of TMS for bipolar depression and present the findings from a two-center open-label prospective trial of TMS in bipolar depression including type I and type II patients. \nAt the end of the presentation\, attendees will gain an understanding of the existing literature on the efficacy of TMS for bipolar depression and learn additional insights from an examination of a two-center open-label trial. \nClinical Outcomes of NeuroStar TMS treatment: The Largest Patient Registry for Depression Treatment with Transcranial Magnetic Stimulation presented by Harold Sackeim\, Ph.D. \nNeuroStar® Advanced Therapy System Clinical Outcomes Registry has documented treatment parameters and clinical outcomes in over 9\,000 unique individuals treated at over 100 private practice sites in the US. This presentation reports new findings regarding the efficacy of TMS in adult patients treated for an episode of major depressive disorder in community settings.  Demographic and treatment parameter correlates of treatment outcomes will be examined.  New findings will also be presented regarding the relative efficacy of the Standard NeuroStar protocol (inter-train interval of 26 s; 38-minute session) and the Dash protocol (inter-train interval of 11 s; 19-minute session). \nAt the end of the presentation\, attendees will gain insights into the real-world treatment outcomes of MDD and the efficacy of TMS leveraging the largest clinical data set in MDD. \nFormat: LIVE \nFREE TO REGISTER! \nRegister online by Monday\, September 28\, 2020. \n**Webinar log-in information will be sent out via email the day prior on September 28\, 2020. \nDisclaimer: The content does not necessarily reflect the views and opinions of Clinical TMS Society or its members and is solely determined by the sponsor. \n\nPresenters: \n\nScott Aaronson\, M.D. \nDr. Scott Aaronson is director of clinical research programs\, director of transcranial magnetic stimulation services\, and chair of the medical executive committee at Sheppard Pratt Health System in Baltimore\, Maryland. He is an Adjunct Professor in the Department of Psychiatry at the University of Maryland School of Medicine. Dr. Aaronson specializes in treatment-resistant affective disorders. He is a thought leader in the areas of biological psychiatry\, diagnosis\, and the integration of somatic and psychological therapies\, and is the principal investigator for multiple studies on the development of novel therapies for mood and anxiety disorders. Dr. Aaronson is a valued speaker and educator and frequently lectures both regionally and nationally on mood disorders\, including the integration of biological and psychotherapies\, complex mood disorders\, psychoeducation\, and the development of new therapies. Much of his research work and publications center on the development of various neurostimulation paradigms including Transcranial Magnetic Stimulation\, Vagus Nerve Stimulation\, Direct Current Stimulation\, and synchronized TMS to treat severe mood disorders.  Recently\, he has begun research into the use of psychedelics in mood disorders including three studies looking at psilocybin in various presentations of depression.  He is a member of the board of directors of the Clinical TMS Society and the American Society for Clinical Psychopharmacology. Dr Aaronson earned his MD with honors from Harvard Medical School. He completed a residency in psychiatry at McLean Hospital\, as well as a fellowship in sleep physiology at Harvard Medical School.  He is a Distinguished Life Fellow of the American Psychiatric Association and a Fellow of the American College of Psychiatrists. \n\nHarold A. Sackeim\, Ph.D. \nDr. Harold A. Sackeim is Professor of Clinical Psychology in Psychiatry and Radiology\, College of Physicians and Surgeons\, Columbia University.  He served as Chief of the Department of Biological Psychiatry at the New York State Psychiatric Institute for 25 years. He is also the Founding Editor of the journal\, Brain Stimulation: Basic\, Translational\, and Clinical Research in Neuromodulation.  He received his first B.A. from Columbia College\, Columbia University (1972)\, another B.A. and an M.A. from Magdalen College\, Oxford University (1974) and his Ph.D. from the University of Pennsylvania (1977)\, where he also completed his clinical training in the Department of Psychiatry. He joined the faculty of Columbia University in 1977\, where he remains today. \n\n\n\nWhen\nSeptember 29th\, 2020 from  5:00 PM to  6:00 PM
URL:https://clinicaltmssociety.org/event/ctmss-product-theater-webinar-with-neurostar/
CATEGORIES:On-Demand Webinars
ATTACH;FMTTYPE=image/jpeg:https://clinicaltmssociety.org/wp-content/uploads/2024/11/NeuroStar_Product_Theater_Event_Thumbnail.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20200902
DTEND;VALUE=DATE:20200903
DTSTAMP:20260423T090019
CREATED:20241107T194804Z
LAST-MODIFIED:20241108T134118Z
UID:1495-1599004800-1599091199@clinicaltmssociety.org
SUMMARY:CTMSS Product Theater Webinar
DESCRIPTION:CTMSS Product Theater Webinar\n \nDate: Tuesday\, September 22\, 2020\nTime: 5:00 pm PDT / 7:00 pm CDT / 8:00 pm EDT \nStimGuide\, An Innovative Solution to Optimize TMS Treatments\nAdoption of 3D Navigation with EMG in the Clinical Practice Setting \nThis session will provide an overview of the workflow for the StimGuide 3D Navigation System and how it can be used in the clinical setting to improve: \n\nPrecise and consistent coil placement\nQuality control and consistency for both novice and expert TMS technicians\nSimplifying MT determination utilizing EMG option\n\nSession Objectives: Upon completion of the presentation\, the participant should have a clear understanding about how 3D navigation and EMG can be used in the clinical setting to optimize TMS treatments\, and how it differs from other navigation systems that require an MRI.  Specifically\, the following aspects will be covered: \n\nRegistration of treatment target(s) and how these can be recalled for subsequent treatment sessions to ensure reliable coil positioning for both novice and expert technicians.\nPositioning the coil in the pre-determined treatment target by aligning the 4 parameters (xy location\, contact\, tilt\, & rotation) within the specified tolerances\nUtilizing EMG to facilitate rMT Determination\nTracking and monitoring coil position in real-time to maintain consistent positioning during a treatment\nHow StimGuide can be used as a quality management tool for clinical sites that have multiple technicians and treaters\n\nFormat: LIVE \nFREE TO REGISTER! \nRegister online by Monday\, September 21\, 2020. \n**Webinar log-in information will be sent out via email the day prior on September 21\, 2020. \nDisclaimer: The content does not necessarily reflect the views and opinions of Clinical TMS Society or its members and is solely determined by the sponsor. \n\nPresenters: \n\nFoster\, Lance C\, MD \nDr. Lance Foster is a Child and Family Psychiatrist at Northwest Arkansas Psychiatry. He is Board Certified in General Psychiatry and also in Child and Adolescent Psychiatry by the American Board of Psychiatry and Neurology. He serves as an adjunct Associate Professor of Psychiatry at the University of Arkansas for Medical Sciences. Dr. Foster is a member of the Clinical TMS Society and provides TMS therapy for patients suffering from depression. Dr. Foster was the Chief Medical Officer and a staff psychiatrist at Ozark Guidance Center for 15 years. As a staff psychiatrist\, he provided psychiatric care for preschool through adult\, Therapeutic Day Treatment programs\, and the Child and Adolescent residential program. Dr. Foster is professionally affiliated with the American Psychiatric Association\, Arkansas Psychiatric Society\, American Academy of Child and Adolescent Psychiatry\, and the American College of Physician Executives. \n\nStaley\, Randall\, MD \nDr. Randall Staley joined Northwest Arkansas Psychiatry in 2018. Dr. Staley is board certified in Child and Adolescent Psychiatry and Adult Psychiatry by the American Board of Psychiatry and Neurology. He has practiced primarily with children and adolescents for more than 10 years\, working with ADHD and other issues in Northwest Arkansas. Dr. Staley is a member of the Clinical TMS Society and provides TMS therapy for patients suffering from depression. \n\n\n\nWhen\nSeptember 22nd\, 2020 from  5:00 PM to  6:00 PM
URL:https://clinicaltmssociety.org/event/1495/
CATEGORIES:On-Demand Webinars
ATTACH;FMTTYPE=image/jpeg:https://clinicaltmssociety.org/wp-content/uploads/2024/11/Magstim_Product_Theater_Event_Thumbnail_V2.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20200803
DTEND;VALUE=DATE:20241108
DTSTAMP:20260423T090019
CREATED:20241107T194636Z
LAST-MODIFIED:20241108T134638Z
UID:1493-1596412800-1731023999@clinicaltmssociety.org
SUMMARY:TOP 6 Flash Poster Presentations Webinar
DESCRIPTION:TOP 6 Flash Poster Presentations Webinar \nTuesday\, August 4\, 2020\n8 pm EDT\, 7 pm CDT and 5 pm PDT\nSince 2018\, CTMSS has provided a speaking platform for the Top 4 Poster Abstracts at the Annual Meeting. We are thrilled to be able to continue to share our top research and findings. \nThe Abstract Review Committee decided to include an additional two abstracts this year to be presented since the 2020 Annual Meeting in Chicago was regrettably canceled. These abstracts were originally scheduled as general presentations for the conference and as such\, were not eligible for being selected to present during this session. Thus\, this year there will be a total of 6 top abstracts presented. \nThe following Top 6 Poster Presentations Webinar is scheduled for Tuesday\, August 4\, 2020\, and will be moderated by our Abstract Review Committee\, F. Andrew Kozel\, M.D.\, M.S.C.R. \n\nAbstract #6: Anhedonia in Major Depressive Disorder: Can it be the Chicken and the Egg for Transcranial Magnetic Stimulation?\nAbstract #17: Does it Matter if Depressed Patients get TMS Sessions Less Often than 5 Times per Week? A Treatment Schedule Density Analysis\nAbstract #25: Systematic Review and Meta-Analysis Comparing iTBS vs. TMS vs. Sham in Randomized Controlled Trials\nAbstract #41: Evaluation of Cognitive Performance in Clinically Depressed Patients Using THINC-it® After rTMS Treatment\nAbstract #45: A Multicenter\, Randomized\, Sham-Controlled Trial of Left Prefrontal\, 10 Hz\, Transcranial Magnetic Stimulation for Adolescents with Treatment-Resistant Depression\nAbstract #64: Stanford Accelerated Intelligent Neuromodulation Therapy (SAINT-TRD) Induces Rapid remission from Treatment-Resistant Depression in a Double-Blinded\, Randomized\, and Controlled Trial\n\nCME will not be provided for this webinar. \nFREE TO REGISTER! \nFormat: Webinar using Zoom Video Communications \n*The Webinar log-in information will be sent out via email the day prior and the morning of the webinar. \nOnline registration ENDS Monday\, August 3\, 2020\, at 3 pm PDT
URL:https://clinicaltmssociety.org/event/top-6-flash-poster-presentations-webinar/
CATEGORIES:On-Demand Webinars
ATTACH;FMTTYPE=image/jpeg:https://clinicaltmssociety.org/wp-content/uploads/2024/11/Top_6_Abstract_Webinar_Recordings.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20200506
DTEND;VALUE=DATE:20200507
DTSTAMP:20260423T090019
CREATED:20241107T194539Z
LAST-MODIFIED:20241108T134210Z
UID:1491-1588723200-1588809599@clinicaltmssociety.org
SUMMARY:2020 Annual Member Meeting Webinar
DESCRIPTION:Please join the Society President\, Todd Hutton\, MD and Executive Director\, Ashleigh Servadio\, MSC\, for the Society’s Annual Member Meeting webinar on Wednesday\, May 6\, 2020 at 4:00 PM (PDT) / 7:00 PM (EDT). \nPresident\, Todd Hutton\, MD will provide a recap of the 2019-2020 year and we will also introduce the newly elected 2020-2021 Board of Directors. \nThis meeting is only for current CTMSS members.
URL:https://clinicaltmssociety.org/event/2020-annual-member-meeting-webinar/
CATEGORIES:On-Demand Webinars
ATTACH;FMTTYPE=image/jpeg:https://clinicaltmssociety.org/wp-content/uploads/2024/11/Annual_Member_Meeting_event_thumbnail.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20191107
DTEND;VALUE=DATE:20191108
DTSTAMP:20260423T090019
CREATED:20241107T194414Z
LAST-MODIFIED:20241108T134715Z
UID:1487-1573084800-1573171199@clinicaltmssociety.org
SUMMARY:2019 Annual Member Meeting Webinar
DESCRIPTION:Please join the Society President\, Todd Hutton\, MD\, Immediate Past President\, Paul Croarkin\, DO and Executive Director\, Ashleigh Servadio\, MSC for the society’s annual members meeting webinar on Wednesday\, July 31\, 2019 at 5:30 PM (PDT). \nListen to updates on the society and learn more about the 2019-2020 Board of Directors. \nThis meeting is only for current CTMSS members. \nNo longer available
URL:https://clinicaltmssociety.org/event/2019-annual-member-meeting-webinar/
CATEGORIES:On-Demand Webinars
ATTACH;FMTTYPE=image/jpeg:https://clinicaltmssociety.org/wp-content/uploads/2024/11/Annual_Member_Meeting_event_thumbnail.jpg
END:VEVENT
END:VCALENDAR